Psoriasis & Psoriatic Arthritis Therapeutics Market By Therapy Type (Topical Therapies, Conventional Systemic Drugs, Targeted Oral Therapies, Biologics, Supportive Anti-Inflammatory Therapies), By Drug Class (TNF-Alpha Inhibitors, IL-17/IL-17 Receptor Inhibitors, IL-23/IL-12 & IL-23 Inhibitors, PDE4 Inhibitors, JAK/TYK2 Inhibitors, Corticosteroids, Other Therapies), By Indication (Plaque Psoriasis, Psoriatic Arthritis, Other Psoriasis Types), By Route of Administration (Topical, Oral, Injectable), By End User (Hospitals, Dermatology Clinics, Rheumatology Clinics, Specialty Clinics, Homecare Settings), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Psoriasis & Psoriatic Arthritis Therapeutics Market: Targeted Treatment, Long-Term Disease Control, and Access Shape Competition

The Global Psoriasis & Psoriatic Arthritis Therapeutics Market was valued at approximately USD 34.8 billion in 2025 and is projected to reach approximately USD 60.0 billion by 2032, expanding at a CAGR of 8.1% during 2026–2032, according to internal projections by Strategic Market Research.

 

Psoriasis and psoriatic arthritis treatments rely on topical corticosteroids and steroid-free creams, conventional systemic medicines, targeted oral therapies, biologic injections, and supportive anti-inflammatory drugs. Treatment selection primarily depends on the severity of skin lesions and joint involvement, with mild disease managed through local therapies and moderate-to-severe cases requiring advanced immune-targeted treatment. 

 

Demand comes from a large group of patients with localized skin disease and a smaller but commercially important population requiring long-term systemic treatment for extensive plaques, recurrent inflammation, or joint involvement. Topical therapies remain the first treatment option for mild-to-moderate psoriasis, while most high-value revenue is generated by targeted oral medicines and biologics.

 

A Large Recurring Patient Pool Sustains Treatment Demand

The Global Burden of Disease 2021 analysis estimated that approximately 43 million people were living with psoriasis worldwide, with about 5.1 million new cases recorded during 2021. Global prevalence increased from 23.1 million cases in 1990, representing an 86.4% rise, while psoriasis-related disability-adjusted life years reached approximately 3.69 million. The expanding diagnosed and recurring patient pool supports sustained demand across topical, oral, and biologic therapies. 

In the United States, psoriasis affects around 3% of adults aged 20 years or older, representing more than 7.5 million adults, while approximately 600,000 adults may remain undiagnosed. Pooled research indicates that approximately one-quarter of people with psoriasis develop psoriatic arthritis, while the National Psoriasis Foundation commonly places the proportion at around 30%. The foundation estimates that as many as 2.4 million Americans live with psoriatic arthritis and that more than 15% of people with psoriasis may have undiagnosed joint disease. 

 

Topicals Remain the Market’s Volume Foundation

Approximately 70% to 80% of people diagnosed with psoriasis have mild-to-moderate disease. This keeps topical therapy central to prescription volume. Corticosteroids, vitamin D analogues, combination products, keratolytics, and moisturising formulations remain widely used because they are familiar to clinicians and generally cost less than systemic alternatives. Nearly one-quarter of plaque psoriasis cases are considered moderate-to-severe, leaving most patients within the potential topical-treatment population.

Corticosteroids such as clobetasol and betamethasone account for a large share of initial prescriptions because they reduce inflammation and visible plaques quickly. Their high utilization is accompanied by treatment burden. Prolonged use of potent corticosteroids can cause skin thinning, symptoms frequently return after treatment stops, and application to the scalp, skin folds, face, or larger body areas can discourage consistent use.

More than one-third of patients have been reported as non-adherent to topical psoriasis treatment. In one electronically monitored eight-week study, adherence declined from 84.6% at the beginning of treatment to 51% by the end. A European study involving 1,291 patients attributed non-adherence to formulation-related concerns in 29% of cases, limited efficacy in 27%, application time in 26%, and adverse reactions in 15%. Products that reduce application frequency or suit sensitive areas can therefore gain adoption without replacing the broader topical standard of care. 

Steroid-free products such as tapinarof and roflumilast are expanding the premium topical category. Their commercial appeal comes from once-daily use and suitability for areas where prolonged use of strong corticosteroids is less desirable. Salicylic acid, urea preparations, and other scale-reducing products retain a companion role through repeat pharmacy and consumer purchases.

 

Approved Immune Pathways Define the Competitive Core

Approved therapeutics across psoriasis and psoriatic arthritis focus on established immune pathways, led by TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Their market relevance differs according to skin-clearing performance, joint control, dosing frequency, safety, biosimilar exposure, and payer preference.

TNF-alpha inhibitors such as adalimumab, etanercept, infliximab, and certolizumab pegol reduce systemic skin and joint inflammation. Their long clinical history supports continued prescribing, particularly in psoriatic arthritis. However, biosimilar competition and payer-led switching are reducing the pricing power of established brands.

IL-17 and IL-17 receptor inhibitors such as secukinumab, ixekizumab, and bimekizumab target a pathway associated with plaque formation and joint inflammation. Bimekizumab differentiates itself through dual inhibition of IL-17A and IL-17F. IL-23 and combined IL-12/23 inhibitors include ustekinumab, guselkumab, tildrakizumab, and risankizumab. These medicines are strongly positioned in plaque psoriasis because of durable skin control and convenient maintenance dosing. Tildrakizumab is approved for plaque psoriasis, while several other agents have labels spanning psoriasis and psoriatic arthritis.

Oral therapy remains important for patients who need systemic control but prefer not to use injections. Apremilast provides an established PDE4 option, while tofacitinib is used in psoriatic arthritis and deucravacitinib targets TYK2 in psoriasis and active psoriatic arthritis. These agents occupy a commercially important middle ground between conventional medicines and biologics.

 

Targeted Oral Therapies Are Reshaping the Treatment Ladder

Conventional systemic therapies continue to play an important role because they are widely available, familiar to clinicians, and generally more affordable than branded targeted treatments. However, their use is limited by the need for regular laboratory monitoring, tolerability issues, and inconsistent skin responses. Methotrexate remains a well-established option, although its ability to clear psoriatic lesions is typically lower than that of many targeted biologic therapies.

Deucravacitinib has strengthened the targeted oral treatment segment. NICE recommends the therapy for selected adults with moderate-to-severe plaque psoriasis who have not responded adequately to other systemic treatments, cannot tolerate them, or are unsuitable for certain biologic therapies.

The product’s commercial scope expanded in March 2026 after the US FDA approved deucravacitinib for adults with active psoriatic arthritis. In two Phase 3 trials involving 670 and 624 patients, 54% of those treated with deucravacitinib achieved an ACR20 response at Week 16, compared with 34% and 39% in the respective placebo groups. The European Commission granted approval in May 2026, enabling Bristol Myers Squibb to position the therapy as an oral targeted treatment for both skin and joint manifestations of psoriatic disease.

Johnson & Johnson expanded this area with icotrokinra. The FDA approved the oral IL-23 receptor antagonist in March 2026 for moderate-to-severe plaque psoriasis in patients aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The approval was supported by four Phase 3 studies involving approximately 2,500 patients. The product introduces an oral approach to a pathway previously associated mainly with injectable biologics. 

 

Emerging Pipeline Moves Toward Oral and Dual-Targeted Treatment

The clinical pipeline is moving toward oral small molecules and dual-targeted biologics designed to improve convenience or deepen pathway control. Sonelokimab is a dual IL-17A and IL-17F inhibitor being evaluated in Phase 3 psoriatic arthritis trials. Its compact molecular format is intended to improve tissue access and extend local engagement, although commercial differentiation will depend on comparative efficacy, safety, dosing, and payer acceptance. 

Icotrokinra is also being evaluated in two Phase 3 trials for active psoriatic arthritis, giving Johnson & Johnson an opportunity to expand the product from skin disease into joint disease. Next-generation TYK2 and JAK1 candidates are being developed with greater pathway selectivity and the objective of approaching biologic-level control in an oral format. 

 

Biologics Continue to Concentrate Market Revenue

Biologics remain the principal revenue-generating category for moderate-to-severe psoriasis and active psoriatic arthritis. Their higher treatment cost, prolonged use, and ability to deliver substantial skin clearance or control multiple joint manifestations support considerably greater revenue per patient than topical treatment.

Competition has moved beyond demonstrating that targeted treatment works. Manufacturers must now show durable responses, manageable dosing, acceptable safety, and activity across skin disease, peripheral joints, enthesitis, dactylitis, and axial symptoms. Multi-indication products have a commercial advantage because physicians can use the same brand across related inflammatory conditions.

UCB’s bimekizumab illustrates the commercial scale available to differentiated biologics. BIMZELX net sales increased from EUR 607 million in 2024 to approximately EUR 2.23 billion in 2025, an increase of more than 200%. More than 116,000 patients had accessed the product, and it was available in more than 50 countries across five approved indications by the end of 2025. Psoriasis generated approximately 53% of sales, while psoriatic arthritis and axial spondyloarthritis contributed additional expansion. 

 

Pricing Pressure Is Changing the Value of Established Brands

The expansion of biologics has increased payer scrutiny of long-term treatment costs. Prior authorization, step therapy, preferred-product contracts, and confidential rebates strongly affect which medicines are initiated.

For 2026, CMS established a negotiated price of USD 2,355 for a 30-day supply of Enbrel, 67% below its 2023 list price. Stelara received a negotiated price of USD 4,695, representing a 66% reduction. The two products generated approximately USD 2.95 billion and USD 2.99 billion in Medicare Part D gross covered prescription costs during 2023 and were used by about 48,000 and 23,000 enrollees, respectively. CMS estimated that the first negotiated medicines would have reduced net spending by approximately USD 6 billion, or 22%, if the prices had applied in 2023. 

 

Specialist Access Influences Therapy Escalation

Psoriasis is commonly managed by dermatologists, while psoriatic arthritis often requires coordination with rheumatologists. HRSA reported approximately 11,555 dermatologists and 5,908 rheumatologists providing patient care in the United States in 2022. This workforce is small relative to the more than 7.5 million US adults with psoriasis and estimated 2.4 million people with psoriatic arthritis, which can delay escalation and contribute to underdiagnosis of joint disease. 

 

Regional Market Dynamics Reflect Access, Pricing, and Specialist Capacity

North America remains a leading commercial region because of its large diagnosed population, early access to targeted medicines, and high biologic use. Its revenue potential is balanced by strict insurance authorization and growing federal pricing intervention.

Europe is supported by specialist care and national reimbursement systems, but adoption is shaped by health technology assessment and cost-effectiveness requirements. Psoriasis prevalence reaches approximately 8% to 11% in some Northern European countries, supporting a sizeable treatment pool, while biosimilar policies increase price competition among older biologics. 

Asia-Pacific offers a large underdiagnosed population but remains uneven in treatment access. Urban centres in Japan, China, South Korea, and Australia provide growing opportunities for targeted treatments, while affordability and specialist shortages sustain lower-cost topical and conventional systemic medicines elsewhere.

 

Competitive Landscape Favors Broad Immunology Portfolios

The competitive landscape includes AbbVie, Johnson & Johnson, Bristol Myers Squibb, UCB, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Samsung Bioepis, and several other biosimilar manufacturers. AbbVie reported global immunology revenue of USD 30.41 billion in 2025, representing year-on-year growth of 14%. Skyrizi generated USD 17.56 billion and accounted for approximately 57.8% of the company’s immunology portfolio, followed by Rinvoq at USD 8.30 billion, or 27.3%, and Humira at USD 4.54 billion, or 14.9%. Although these figures include revenue from all approved indications, they illustrate the commercial scale available to companies with diversified immune-mediated disease portfolios.

Competitive strength now depends on more than clinical efficacy. Broad reimbursement coverage, real-world evidence, strong specialist relationships, treatment persistence, and the ability to protect net pricing increasingly determine market performance. Companies with therapies approved across psoriasis, psoriatic arthritis, and related inflammatory conditions can extend product lifecycles while serving multiple specialist channels through a shared commercial infrastructure.

 

Strategic Outlook: Innovation, Access, and Long-Term Disease Management

The market will remain divided between high-volume local treatment and high-value systemic disease control. Generic corticosteroids will retain a large prescription base, while steroid-free topicals gain from concerns around recurrence and prolonged steroid exposure.

Targeted oral medicines will challenge injectable biologics where they provide strong disease control with simpler administration. Products approved across both psoriasis and psoriatic arthritis will be better positioned to retain patients as disease manifestations progress and treatment requirements change.

Biologics will continue to generate the greatest revenue per treated patient, but pricing flexibility will become as important as clinical differentiation. Medicare negotiation, biosimilar expansion, national health technology assessments, and insurer step-therapy policies will continue to pressure established brands.

 

Psoriasis & Psoriatic Arthritis Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 34.8 Billion
Revenue Forecast in 2032	USD 60.0 Billion
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Therapy Type, By Drug Class, By Indication, By Route of Administration, By End User, By Geography
By Therapy Type	Topical Therapies, Conventional Systemic Drugs, Targeted Oral Therapies, Biologics, Supportive Anti-Inflammatory Therapies
By Drug Class	TNF-Alpha Inhibitors, IL-17/IL-17 Receptor Inhibitors, IL-23/IL-12 & IL-23 Inhibitors, PDE4 Inhibitors, JAK/TYK2 Inhibitors, Corticosteroids, Other Therapies
By Indication	Plaque Psoriasis, Psoriatic Arthritis, Other Psoriasis Types
By Route of Administration	Topical, Oral, Injectable
By End User	Hospitals, Dermatology Clinics, Rheumatology Clinics, Specialty Clinics, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Switzerland, Netherlands, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising psoriasis and psoriatic arthritis prevalence, increasing adoption of biologic and targeted oral therapies, expansion of immune pathway-based treatments, growing demand for long-term disease control, increasing diagnosis of psoriatic arthritis, biosimilar availability, and improved access to specialty care
Customization Option	Available upon request